ISV Member Newsletter May 2025

Download PDF

FROM THE PRESIDENTS DESK

Dear Colleagues and Members of the International Society of Vaccines (ISV),

I am excited that preparations are well underway to welcome delegates to the **2025 ISV Annual Congress**, taking place from **October 28–30, 2025**, at the **Protea Hotel in Stellenbosch, South Africa**. Set in the heart of South Africa's stunning winelands, ISV 2025 will be a world-class gathering of global leaders in vaccine science, offering a unique platform for industry, academic researchers, and early-career scientists to connect, share breakthroughs, and shape the future of vaccinology.

This year's Congress holds particular significance for the ISV, as it will be held on the **African continent for the very first time.** By bringing the global vaccine community to Africa, we aim to:

- **Showcase mutual scientific innovation**
- **Foster new collaborations and capacity-building**
- **Facilitate solution-driven dialogue to accelerate vaccine development for today's most critical emerging and re-emerging infectious threats**

Our co-chairs and scientific committee (see: https://www.isvcongress2025.co.za) have curated an exciting program. I'm particularly honoured to announce our keynote speakers:

- **Dr. Drew Weissman** (University of Pennsylvania), 2023 Nobel Laureate in Physiology or Medicine, will speak on *Nucleoside-modified mRNA-LNP therapeutics*.
- **Dr. Willem Hanekom** (Africa Health Research Institute) will address *Novel TB vaccines* with global game-changing potential.

- **Dr. Linda-Gail Bekker** (Director, Desmond Tutu Health Foundation, South Africa) will deliver the prestigious **Stanley Plotkin Lecture**, recognizing her longstanding contributions to HIV prevention, treatment, and advocacy.

We are also proud to welcome an **outstanding group of invited speakers** covering cutting-edge topics such as:

- AI-based engineering for vaccine design
- Systems vaccinology for vaccine development
- Climate change and emerging One Health threats
- Innovations in maternal and newborn vaccination
- Therapeutic cancer vaccines
- Innovations in vaccine manufacturing- the future for scalable production

Our **parallel sessions** will feature a large number of presentations selected from submitted abstracts, showcasing the full spectrum of vaccinology — from basic science and breakthrough technologies to clinical trials and real-world implementation.

A personal highlight of the Congress is the **'Bright Sparks in Vaccinology'** sessions. These dynamic oral and poster presentations by PhD students and post-doctoral fellows highlight the vibrant, diverse talent pipeline in our field. These friendly competitions are a great opportunity to win prizes, boost your CV, and gain recognition. We also continue our commitment to Early Career Researcher (ECR) development through dedicated **career and mentorship sessions**.

We are deeply grateful to our partners —**CEPI, the Gates Foundation, the International Vaccine Institute (IVI), and the International Veterinary Vaccine Network (IVVN)**— and to all the generous donors who have made it possible to offer **travel scholarships** for PhD students and ECRs, as well as support for invited international speakers.

Huge thanks to our **sponsors**, ISV is able to sustain its mission to connect scientists across career stages to the latest advancements in vaccine science through this Annual Congress.

There is a lot of exciting science to look forward to! - I encourage you to **submit your abstracts**, **register early**, and help us spread the word. For full details and important deadlines, visit the Congress website: www.isvcongress2025.co.za.

And while you're in South Africa, why not take an extra day or two to explore the **Cape Winelands**, **Table Mountain**, or even enjoy a **safari**?

We can't wait to welcome you to Stellenbosch for what promises to be an unforgettable ISV 2025 Congress.

Warmest regards,

Linda Klavinskis, President, International Society for Vaccines

SUBMIT YOUR ABSTRACT!

Deadline Extended: 24 June 2025

Please submit your abstract by 24 June 2025 if you wish to be considered for an oral (15 min) or poster presentation at the 2025 ISV Annual Congress. You may submit your abstract by clicking the button below or by visiting the abstract submission page on the ISV Congress Website.

Can't attend Congress in-person? Do not let that stop you from submitting your abstract for a virtual poster. Virtual posters will be uploaded for attendees to view across the globe!

Please be sure to follow the technical instructions when you submit your abstract.

Submit Abstract

REGISTER PRIOR TO EARLY BIRD DEADLINE

Early Bird Deadline: 15 August 2025

Please register early to benefit from the early-bird discount to regular registration rates. Members of the ISV receive a further USD$100 discount on registration.

Join or Renew ISV Membership

Register for Congress

CAN'T ATTEND IN-PERSON?

As a hybrid conference, the ISV Virtual Platform provides a highly interactive Congress experience for in-person and online attendees to connect, exchange information, and access the following content:

- Congress speaker presentation recordings which will be uploaded to the Virtual Platform shortly after they are presented.
- Virtual posters
- Virtual exhibit booths
- Ability to search all virtual attendees and chat directly and/or set up private meetings.

All in-person attendees will receive access to the Virtual Platform.

REMINDER!
UPCOMING ISV BOARD MEMBER ELECTIONS (2026-2027)

(For details see March Newsletter)

To signal your interest, please email Edward Gibson (ISV Director of Operations) at edwardgibson@isvcongress.org who can provide the nomination form for review by the nominations committee.

ISV BOARD MEMBER INTRODUCTION

Shan Lu

UMASS Chan Medical School / Worcester HIV Vaccine (WHV)

What is your background/profession?

I was first trained as a physician and was one of the first-class students being admitted to formal medical schools in China after the disastrous Culture Revolution. I was also one of the first group of students from China coming to US in 1980s to pursue graduate education. I stayed with the University of Massachusetts Medical School for the entire 40 years, receiving my PhD in immunology, postdoctoral fellowship in virology, residency in Internal Medicine, and later becoming a board-certified attending physician and a tenured full professor, before becoming an Emeritus Professor after my formal retirement. I also completed business school night classes and received an MBA specializing in health administration.

What is your favorite/main research area/topic?

Vaccinology is definitely my love and dedicated research area. It combines my education and training in immunology, virology, and medicine together. I was very fortunate by joining the discovery of DNA vaccine technology in early part of my postdoctoral training and continued the nucleic acid vaccine research and development since then without looking back.

What's your main scientific achievement/s?

I participated in the discovery and continued promotion of DNA vaccines for over 30 years. Based on the lessons learned from the field, I have been pushing for the Heterologous Prime-Boost Vaccination concept in the last two decades which became well accepted after the COVID outbreak in an effort to develop more effective vaccines. I applied this concept by developing a polyvalent DNA prime-protein boost HIV vaccine (PDPHV) and moved this vaccine into multiple human clinical studies which showed the most potent and cross-reactive immune responses among previous candidate HIV vaccines. A phase 2 study is being planned for study in South Africa in 2025.

Do you have any hidden talent/s?

While I started learning to play piano at the age of 4, the life changes in China (and later with studies and work schedule) did not allow me to play it again. Now I serve as a part time gardener to take care the fruit trees my wife planted in recent years.

ISV COMMITTEE MEMBER INTRODUCTIONS

Sita Awasthi

Outreach and Public Engagement Committee /
Paper of the Month & Webinar Steering Sub Committees

What is your background/profession?

After finishing my bachelors and Masters in Biochemistry, I initiated my doctoral degree in biochemistry in Devi Ahilya University in India. For post-doctoral training, I moved to United States and developed expertise in RNA splicing, human viruses and human immunity. I joined Infectious Disease Division, Department of Medicine at Perelman School of Medicine, University of Pennsylvania, Philadelphia USA as an Assistant professor Research and currently serving as associate professor research in the same division.

What is your favorite/main research area/topic?

One of my favorite research topics is human herpes viruses. Human herpes viruses are known to develop latency in human hosts and reactivate when host immune defenses are down. Moreover, human herpes viruses have evolved in humans for millions of years and therefore developed strategies to evade human immune responses even in the individuals with intact immunity. Investigating these immune evasion strategies and applying that knowledge for developing prevention and therapeutic vaccine is extremely interesting to me.

What's your main scientific achievement/s?

One of my main scientific achievements is the exploration of strategies where virus is no longer able to evade the human immune response and use these tactics to develop a candidate vaccine for prevention of genital herpes disease using various animal models. We used many vaccine technology platforms and show that mRNA-LNP technology outperform traditional, attenuated viral vaccine, protein-adjuvant vaccine in preventing genital herpes. All pre-clinical work was done with many collaborators and build up on the knowledge base acquired by many dedicated scientists before and during my time.

Do you have any hidden talent/s?

Three Michelin star worth creative and healthy cooking, dancing for fun and long-distance bicycle riding.

Alejandro Capozzo

Outreach and Public Engagement Committee

What is your background/profession?

I am a biologist specialized in biotechnology. I studied at the University of Buenos Aires, where I also completed my PhD. I did my post-doc in Vaccinology at the Center for Vaccine Deveopment, University of Maryland in Baltimore.

What is your favorite/main research area/topic?

I work in applied immunology, with a particular fascination for how the immune system responds to different vaccines and formulations. I'm especially intrigued by how targeting the innate immune system can dramatically shape the adaptive response. Understanding how to generate strong, long-lasting immunological memory remains one of the most compelling challenges—we're clearly missing something fundamental.

What's your main scientific achievement/s?

I have developed several simple assays to help better understand the immune response to foot-and-mouth disease vaccine in cattle. I've also explored basic aspects of both innate and adaptive immunity. However, what I consider my most meaningful achievement is building a Latin American network to promote veterinary immunology in the region.

I also greatly valued my time as CEO of the Global Foot-and-Mouth Disease Research Alliance. I am proud to be part of a team that supports researchers from low- and middle-income countries—like myself—in advancing their careers, traveling, and connecting with colleagues from around the world.

Currently, as a member of the Outreach Committee of the International Society for Vaccines (ISV), I am committed to promoting knowledge on vaccine technologies, applied immunology, and the One Health concept, which now guides much of my research.

I am now the director of a research center in Argentina focused on One Health. I lead several teams, each with their own principal investigators—many of them talented young women and men whom I am proud to support and mentor. That is, perhaps, the achievement that brings me the greatest satisfaction.

Do you have any hidden talent/s?

A few—and they're well hidden! I'm a 100% social person and naturally diplomatic. Diplomacy is definitely one of my strengths, though perhaps not so hidden. I'm also a great cook and a good listener—both talents I value highly in and out of the lab.

And I have a special (and slightly mischievous) talent for giving people nicknames—so much so that I sometimes forget their real names!

Corey Fang

Vaccine Industry Interaction Committee

What is your background/profession?

I obtained my Pharm.D in New York at St. John's University and completed a post-doc fellowship with Rutgers University in New Jersey. I am currently the Global Medical Affairs Lead for External Engagement at AstraZeneca for our Infectious Disease Portfolio.

What is your favorite/main research area/topic?

I am interested in access, education and increasing quality of life for patients. This has led me to work on cardio-metabolic diseases such as coronary artery disease and type 2 diabetes. Since the COVID-19 pandemic, I have been interested in ensuring we build evidence for various infectious diseases and high-risk populations including the

immunocompromised and patients with various comorbidities including those mentioned earlier.

What's your main scientific achievement/s?

Working on ensuring immunocompromised patients across the US were able to access to preventative monoclonal antibodies as an additional layer of protection during the COVID-19 pandemic and appropriately educate physicians across specialties. It is important to note that this was a major team effort and I was happy to be part of that journey.

Do you have any hidden talent/s?

I have a major green thumb and knack for bringing plants back to life and often revive plants for family and friends.

ISV COMMITTEE UPDATE

Next Generation Vaccinologist Committee

Martin Beukema
University Medical Center Groningen

Céline Lemoine
Vaccine Formulation Institute

Allegra Paletta
Vaccine Formulation Institute

Omolara Baiyegunhi
African Health Research Institute

Alper Cevirgel
National Institute for Public Health and the Environment of the Netherlands

Sandra Depelsenaire
Vaxxas



Ebony Gary
The Wistar Institute

Arturo Liñan Torres
Universidad Nacional Autónoma de México

Ilke Aernout
Ghent University



Tatenda Chikowore
Africa Health Research Insititute (AHRI)

Sajo Mohammed Usman
University of Maiduguri

Alcidia Ramos Barros
The University of Geneva

Senior ISV Members

Jean Boyer
Agenta Therapeutics

Anke Huckriede
University Medical Center Groningen

Michael Schotsaert
Ichan School of Medicine, Mount Sinai

Building Bridges in Vaccine Science: The Next Generation Vaccinologists

The future of vaccinology depends not only on cutting-edge science but also on strong, supportive networks that foster growth, innovation, and collaboration. That's the driving force behind *Next Generation Vaccinologists* (**NextGenVacc**), a vibrant group within the International Society for Vaccines (ISV) dedicated to supporting early career researchers (ECRs) in the field. Our goal is simple: to empower the next generation of vaccinologists to thrive — not just as scientists, but as leaders, communicators, and collaborators. Whether you're an ECR seeking community and guidance or a senior researcher hoping to give back and shape the future of the field, there's a place for you in the NextGenVacc community!

At NextGenVacc, we believe the path to impactful science is best walked together. With this in mind, we launched the **NextGenVacc Webinar Series** — monthly

sessions that bring together hundreds of attendees from around the world. These webinars spotlight rising voices in vaccinology and pair them with established leaders who share insights, career journeys, and technical expertise. We also invite experts to speak on grant writing, mentorship, cutting-edge vaccine technology, and academic careers beyond the bench.

In our **May webinar**, attended by 125 participants, we featured **Dr. Renske Hesselink** from CEPI, who spoke about grant writing for foundations, and **Dr. Lisa Opsomer** from the University of Ghent, who lectured on cutting-edge self-amplifying RNA vaccine technology.

In our **June webinar**, we're excited to host **Dr. Dennis Christensen** (CRODA), who will discuss academia-industry collaborations and transitioning into industry, and **Dr. Nina Nguyen** (Statens Serum Institute, Denmark), who will present on adjuvants and the discovery of CAF. Join us on **June 12 at 4:00 PM CET** for an engaging session designed to spark conversation and connection across sectors. Please join us through the following link: https://lnkd.in/eY24XJtk

NextGenVacc works closely with the **ISV Mentorship Program**, led by Drs. Jean Boyer and Michael Schotsaert. This program thoughtfully matches ECRs with interest- and value-aligned mentors to guide them in their careers. Through this approach, participants receive tailored career support, fostering professional relationships that transcend disciplinary and geographic boundaries.If you are interested in joining our community, speaking in an upcoming webinar, or would like to benefit from the mentorship program, do not hesitate to reach out (nextgenvacc@gmail.com). You can find us online @NextGenVacc or on LinkedIn and WhatsApp below!

Stay connected, stay curious, and join us in building the future of vaccines!

LinkedIn: Link Whatsapp: Link

VACCINE NEWS FLASH

Danilo Casimiro
Sanofi

Corey Fang
AstraZeneca

On **May 9**, the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) on May 9 recommended a pause in the use of Valneva's chikungunya vaccine (IXCHIQ) in people ages 60 and older while officials investigate severe adverse events, some neurologic and cardiac, in vaccine recipients. 17 severe adverse events, 2 of them fatal, have been reported globally in people ages 62 to 89 years who received the vaccine. 6 were from the United States. The FDA said it will conduct an updated risk-benefit assessment. Valneva's vaccine is the first approved Chikungunya vaccine; a second chikungunya vaccine (VIMKUNYA) based on recombinant virus-like particle was approved earlier in February 2025 and is marketed by Bavarian Nordic.

On **May 15**, a collaborative program led by scientists at IAVI and the Scripps Research Institute reported in *Science* a clinical proof of concept for the use of stepwise vaccination strategy using different env antigens delivered using mRNA platform for induction of broadly neutralizing HIV antibodies. The two Phase 1 human clinical trials assessed the safety and immunogenicity of the approach as priming immunogens (both trials) and boosting immunogens (1 trial). Priming dose induced broadly neutralizing neutralizing antibody (bnAb) precursors with substantial frequencies and somatic hypermutations (SHM), and heterologous dosing produced increased SHM, affinity, and neutralization activity toward bnAb development.

On **May 16**, the FDA issued the approval of Novavax's COVID-19 vaccine with specific restrictions. Novavax makes a traditional recombinant protein-based coronavirus vaccine – and until now it had emergency authorization from FDA for use in anyone 12 and older. The FDA granted the company full approval for its vaccine for use only in adults 65 and older – or those 12 to 64 who have at least one health problem that puts them at increased risk from COVID-19.

On **May 20**, FDA unveiled new stricter framework for COVID-19 vaccine approval during their townhall (recording here) and subsequent perspective piece in NEJM. The bottom line is going forward, Covid-19 vaccines will only be recommended via immunobridging studies for people over 65 or with at least one chronic condition. If manufacturers want to offer updated vaccines to younger adults, they must run a new placebo-controlled trial after a variant arrives. Questions will arise in the coming

months as the ACIP makes its decision and how health insurers will react leading to access change across the US. IDSA released a statement on May 27 urging health plans to keep access open to all patients (link)

On **May 22**, the FDA recommended the COVID-19 vaccine manufacturers tailor their shots for the upcoming fall and winter season to target the "JN.1" strain, ideally a subvariant known as LP.8.1.

On **May 23**, the FDA approved an expanded indication for Sanofi's MenQuadfi meningococcal vaccine—for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroups A, C, W, and Y—that now has been extended down to children aged 6 weeks to 23 months. The approval expanded on the previous indication for individuals aged 2 years or older. Over the last couple of years, there has been a significant increase in the amount of meningococcal disease that's being seen here in the United States, the majority of disease seen now is serotype Y. Individuals at the highest risk are young infants, in addition to individuals like college students, people in military barracks, or teenagers who have other risk factors for disease.

On **May 26**, the European Commission (EC) has approved Merck's Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for active immunization against invasive disease and pneumonia caused by *Streptococcus pneumoniae* in individuals aged 18 and older. The vaccine covers 8 strains which are not covered by other pneumococcal vaccine products. This authorization permits the vaccine's marketing across all EU member states.

2024 PhD STUDENT & EARLY CAREER RESEARCHER CONGRESS AWARD RECIPIENTS: REFLECTIONS

Lara Kelchtermans, *KU Leuven, Belgium*

Awards for PhD Students and Early Career Researchers from Non-LMICs to Attend the ISV Congress ***(Supported by ISV)***

Awarded: 3rd Place - PhD Poster Award

Presentation Title: *Broad filovirus protection via NK cell activation and neutrophil phagocytosis in mice induced by a YF17D-vectored Sudan virus vaccine.*

By attending the international Society for Vaccines congress, I gained invaluable insights in the latest advances in vaccine research. The wide range of topics presented broadened my perspective, particularly as I learned how eosinophils can influence disease outcomes—a cell population I had previously considered irrelevant to vaccine immunology. I also gained

deeper insights into areas more closely related to my own research, such as the role of viral Fcγ receptors in immune evasion during CMV infection. Observing world-leading experts in the field, witnessing on how they present their research and which directions they pursue for the development of the next generation of vaccines was truly inspiring.

The ISV meeting also offered me a platform to share my own research through a poster and presentation. Engaging in discussions with peers during these instances led me to critically reflect on and refine certain aspects of my work. The positive feedback I received was motivating, encouraging me to expand my research further and explore new methodologies. Moreover, the network opportunities sparked some ideas for future collaborations. As a highlight, the poster presentation award provided extra recognition for my work, which was very rewarding. Overall, the experience was immensely beneficial for my professional development, and I am grateful for the travel grant that made my participation possible.

Gyunghee Jo, *Scripps Research Institute, USA*

Awards for PhD Students and Early Career Researchers from Non-LMICs to Attend the ISV Congress ***(Supported by ISV)***

Awarded: 2nd Place - Early Career Researcher Poster Award

Presentation Title: *Structural basis of broad protection against influenza virus by a human antibody targeting the neuraminidase active site through a recurring motif in CDR-H3*

Attending the ISV 2024 Annual Congress, held in my home country of South Korea, was an invaluable experience that significantly contributed to my professional development and research goals. The Congress provided an exceptional platform to present my research titled "Structural basis of broad

protection against influenza virus by a human antibody targeting the neuraminidase active site through a recurring motif in CDR-H3" as both an oral presentation and a poster presentation. These opportunities allowed me to share my findings with a diverse audience and receive thoughtful questions and constructive feedback from leading experts in the field.

The feedback and discussions during my presentations provided valuable perspectives on the recurring molecular features in antibody responses and their implications for universal vaccine design. This input has helped refine my current research on influenza neuraminidase antibodies and inspired new directions for future studies.

As part of this meaningful experience, I received two awards, the Travel Award and the 2nd place ECR Poster Presenter Award. The Travel Award provided essential support that enabled me to travel from the United States to South Korea and attend the Congress, while the Poster Award recognized the significance of my research and encourages me to continue pursuing impactful work.

As the Congress was held in South Korea, I had the unique opportunity to network not only with leading researchers from around the world but also with prominent scientists from my home country. These interactions were particularly valuable, as they allowed me to establish connections within South Korea's research community, which will be instrumental when I return to continue my career. The opportunity to engage with both local and international scientists has provided new ideas and potential directions for future research.

Overall, the ISV 2024 Annual Congress reinforced my commitment to advancing vaccine research and provided new tools, ideas, and connections to help achieve this goal. I am deeply grateful for the opportunity to participate and for the support that made this experience possible.

ISV NEXT GERNERATION WEBINAR SERIES

12 JUNE 2025



JOIN HERE

12 June 2025
07:00 (PDT) | 10:00 (EDT) | 15:00 (BST) | 16:00 (CEST) | 16:00 (SAST) | 19:30 (IST) | 22:00 (CST) | 23:00 (KST)

13 June 2025
00:00 (AEST)

Join Here

26 June 2025

06:00 (PDT) | 09:00 (EDT) | 14:00 (BST) | 15:00 (CEST) | 15:00 (SAST) | 18:30 (IST) | 21:00 (CST) | 22:00 (KST) | 23:00 (AEST)

ISV WEBINAR SERIES

JUNE 2025

(DATE & TIME TO BE CONFIRMED)



ISV PAPERS OF THE MONTH

The ISV Outreach Committee Members review vaccine literature published in the last month and nominate 2-3 papers for consideration. Committee Members then vote on the nominated papers and the paper receiving the majority of votes is selected as the paper of the month.

APRIL 2025 PAPER OF THE MONTH

Vaccine-enhanced competition permits rational bacterial strain replacement in the gut

Science. 2025 Apr 4;388(6742):74-81. doi: 10.1126/science.adp5011. Epub 2025 Apr 3. PMID: 40179176.

Authors
Lentsch V, Woller A, Rocker A, Aslani S, Moresi C, Ruoho N, Larsson L, Fattinger SA, Wenner N, Barazzone EC, Hardt WD, Loverdo C, Diard M, Slack E.

Abstract
Colonization of the intestinal lumen precedes invasive infection for a wide range of enteropathogenic and opportunistic pathogenic bacteria. We show that combining oral vaccination with engineered or selected niche-competitor strains permits pathogen exclusion and strain replacement in the mouse gut lumen. This approach can be applied either prophylactically to prevent invasion of nontyphoidal *Salmonella* strains, or therapeutically to displace an established *Escherichia coli.* Both intact adaptive immunity and metabolic niche

competition are necessary for efficient vaccine-enhanced competition. Our findings imply that mucosal antibodies have evolved to work in the context of gut microbial ecology by influencing the outcome of competition. This has broad implications for the elimination of pathogenic and antibiotic-resistant bacterial reservoirs and for rational microbiota engineering.

MAY 2025 PAPER OF THE MONTH

A natural experiment on the effect of herpes zoster vaccination on dementia

Nature. 2025 May;641(8062):438-446. doi: 10.1038/s41586-025-08800-x. Epub 2025 Apr 2. PMID: 40175543; PMCID: PMC12058522.

Authors
Eyting M, Xie M, Michalik F, Heß S, Chung S, Geldsetzer P..

Abstract
Neurotropic herpesviruses may be implicated in the development of dementia[1-5]. Moreover, vaccines may have important off-target immunological effects[6-9]. Here we aim to determine the effect of live-attenuated herpes zoster vaccination on the occurrence of dementia diagnoses. To provide causal as opposed to correlational evidence, we take advantage of the fact that, in Wales, eligibility for the zoster vaccine was determined on the basis of an individual's exact date of birth. Those born before 2 September 1933 were ineligible and remained ineligible for life, whereas those born on or after 2 September 1933 were eligible for at least 1 year to receive the vaccine. Using large-scale electronic health record data, we first show that the percentage of adults who received the vaccine increased from 0.01% among patients who were merely 1 week too old to be eligible, to 47.2% among those who were just 1 week younger. Apart from this large difference in the probability of ever receiving the zoster vaccine, individuals born just 1 week before 2 September 1933 are unlikely to differ systematically from those born 1 week later. Using these comparison groups in a regression discontinuity design, we show that receiving the zoster vaccine reduced the probability of a new dementia diagnosis over a follow-up period of 7 years by 3.5 percentage points (95% confidence interval (CI) = 0.6-7.1, P = 0.019), corresponding to a 20.0% (95% CI = 6.5-33.4) relative reduction. This protective effect was stronger among women than men. We successfully confirm our findings in a different population (England and Wales's combined population), with a different type of data (death certificates) and using an outcome (deaths with dementia as primary cause) that is closely related to dementia, but less reliant on a timely diagnosis of dementia by the healthcare system[10]. Through the use of a unique natural experiment, this study provides evidence of a dementia-preventing or dementia-delaying effect from zoster vaccination that is less vulnerable to confounding and bias than the existing associational evidence.

Click HERE to View Prior Papers of the Month and Year

ISV WELCOMES ITS NEWEST MEMBERS

Matthew Bottomley
Timothy Chege
Chelsea Crooks
Erica Dawson
Anna Durbin
Orene Greer
Cong Hieu Truong
Leigh Howard
Baoming Jiang
Chikondi Kandulu
Nana-Marie Lemm
Andrea Majstorovic
Belkys Maletto
Mitali Mishra
Carolina Padula
ThanhTam Pham
Bali Pulendran
Alcidia Ramos Barros
Alexandra Sanchez-Martinez
Phyumar Soe
Ivana Stolfa
Xingmin Sun
Tara Wagner-Gamble
Ruijie Wang
Holly Wilson
Ayesha Zahid
Xuefei Zhou
Gabriela Samayoa
Weixiao Wang
Peter Anderson
Boston Zimba
Adam Snook

Encourage your Colleagues and Peers to Join or Renew their ISV Membership Today!

www.isv-online.org

ISV Member Benefits

- Reduced registration fee to the ISV Annual Congress
- Receive ISV members-only Newsletter, and submit news and articles for distribution in the newsletter
- Eligibility to run for ISV Officer and Board positions
- Opportunity to network and collaborate with global vaccine researchers and organizations
- Participate in various ISV Committees including Awards & Prizes; Education & Membership; Global Equity & Engagement; Industry Interaction; and Outreach and Public Engagement
- Access to career mentorship for early-career researchers
- Review and vote on Papers of the Month and Paper of the Year
- Access to online version of the journal *Vaccine* (upon request)
- 15% APC discount on the journal, *Human Vaccines and Immunotherapeutics*

To apply for the ISV Member benefit of a 15% discount to the Article Publishing Charge for the open access journal, Human Vaccines and Immunotherapeutics, contact info@isv-online.org to be provided with the guide and instructions. (A 50% discount is applicable to scientists from lower-middle-income countries; researchers from low-income countries are eligible for a full waiver (100% discount).

Stay Engaged with the ISV through its Social Media Channels:

ISV on LinkedIn

ISV on Facebook

ISV on Instagram

ISV on X

ISV on Bluesky

PARTNER

International Vaccine Institute

Bill & Melinda Gates foundation

National Research Council Canada

International Veterinary Vaccinology Network

CEPI

Afrigen Biologics & Vaccines

GOLD

sanofi

GPN VACCINES

human VACCINES & IMMUNOTHERAPEUTICS

Pfizer

DYNAVAX

BAVARIAN NORDIC

VISMEDERI

ANALYSES FOR LIFE IMPROVEMENT

SILVER

MABTECH

INOVIO

OTHER SUPPORT

BLUE LAKE BIOTECHNOLOGY